Aprogen Biologics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 1,169.82 million compared to KRW 184.57 million a year ago. Net loss was KRW 118,269.72 million compared to net income of KRW 12,639.36 million a year ago.

Basic loss per share from continuing operations was KRW 1,870 compared to basic earnings per share from continuing operations of KRW 310 a year ago. Diluted loss per share from continuing operations was KRW 1,870 compared to diluted earnings per share from continuing operations of KRW 310 a year ago. Basic loss per share was KRW 1,870 compared to basic earnings per share of KRW 310 a year ago.